ELCC 2016: LUX-Lung 7 – phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC

ELCC 2016: LUX-Lung 7 – phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC

VJOncology

4 years
420 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Kenneth O'Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses LUX-Lung 7, a phase 2b, global, randomized, open-label trial of afatinib compared with gefitinib as first-line treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Up Next Autoplay